Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943292 | 0.83 | RAB9A (0.51) | HPGDRAB9AALDH1A1TDP1 | |
| SCHEMBL4574595 | 0.80 | LMNA (0.46) | HPGDRAB9AALDH1A1TSHR | |
| SCHEMBL4574791 | 0.80 | MEN1 (0.45) | HPGDRAB9AALDH1A1 | |
| SCHEMBL21148184 | 0.80 | HPGD (0.46) | HPGDRAB9AALDH1A1TSHRALOX15 | |
| SCHEMBL5776033 | 0.79 | CES2 (0.46) | RAB9AALDH1A1TSHRTDP1 | |
| SCHEMBL4735120 | 0.75 | HTT (0.56) | HPGDRAB9AALDH1A1TDP1ALOX15 | |
| SCHEMBL1942112 | 0.74 | ALOX5 (0.51) | HPGDRAB9AALDH1A1TSHRTDP1 | |
| SCHEMBL14041122 | 0.72 | CES2 (0.39) | ALDH1A1TDP1ALOX5 | |
| SCHEMBL26143931 | 0.72 | ALDH1A1 (0.44) | HPGDALDH1A1TSHR | |
| SCHEMBL18509991 | 0.71 | SLC6A1 (0.32) | HPGDRAB9AALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | NYCOMED GMBH (DE) | 2008-11-13 | — | — | US | disclosed |
| EP-1904454-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | Nycomed GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2006136552-A2 | PROCESS FOR THE PRODUCTION OF INTERMADIATES FOR THE PREPARATION OF TRICYCLIC BENZIMIDAZOLES | NYCOMED GMBH (DE) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280855-A1 | Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles | CYP1B1, CYP1A1, CYP3A4 | HPGD 906/4885RAB9A 2427/4885ALDH1A1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.